Toxicology
iC42 Clinical Research and Development is a service center at the University of Colorado established by the School of Medicine’s Department of Anesthesiology in 2001.
iC42 was created to be a leader in the evaluation of pharmacokinetics, drug metabolism and the development of clinical diagnostic tools.
Our team carries out research and development projects including molecular marker discovery, translational research, strategy development and the identification of molecular mechanisms.
We are always interested in projects in proteomics, metabolomics, molecular markers, custom methodologies and pediatric pharmacokinetics.
We encourage and seek out successful collaborations and strategic partnerships . Currently, iC42 collaborates with more than 40 entities including academic groups, biotech and pharmaceutical companies all over the world.
High-end Bioanalytic Services
iC42 Clinical Research & Development has developed into a global resource for high-end bioanalytics that currently collaborates with more than 40 entities including academic groups, clinical networks, biotech and pharmaceutical companies all over the world.
- Quantitative Bioanalytics Methods
- Assay Development and Validation (following FDA, ICH/EMEA and CLSI guidances)
- LC-MS/MS Quantification of Endogenous Compounds
- Amino Acids High Energy Phosphates (LC-MS)
- Fatty Acid Profiling (GC-MS)
- Metabolic Profiling (“non-targeted metabolomics, GC-MS, LC-high resolution MS, 1H NMR)
- Targeted Metabolic Pathway Screening (“multiplexing” LC-MS/MS)
- High Energy Phosphates (31P NMR)
- Lipid Patterns (1H NMR)
- 13C-labeled tracers (13C NMR, “Fluxomics”)
- Isotope Ratio Mass Spectrometry and Measurement of Isotope Enrichment
- Non-Targeted Proteomics
- Targeted Quantification of Peptides and Proteins
- Drug Metabolism
- Purified and Certified Immunosuppressant Metabolites